Provided by Tiger Fintech (Singapore) Pte. Ltd.

Halozyme Therapeutics

48.10
-2.1307-4.24%
Volume:3.25M
Turnover:158.25M
Market Cap:5.93B
PE:12.80
High:50.17
Open:50.08
Low:47.80
Close:50.23
Loading ...

Analysts Conflicted on These Healthcare Names: Halozyme (HALO), Stoke Therapeutics (STOK) and Lantheus (LNTH)

TIPRANKS
·
23 Feb

Analysts Conflicted on These Healthcare Names: Halozyme (HALO), Walgreens Boots Alliance (WBA) and Axsome Therapeutics (AXSM)

TIPRANKS
·
23 Feb

Halozyme Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
20 Feb

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), GeneDx Holdings (WGS) and Bausch + Lomb Corporation (BLCO)

TIPRANKS
·
20 Feb

Halozyme Therapeutics: Record Earnings and Future Growth

TIPRANKS
·
20 Feb

Halozyme Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
19 Feb

Q4 2024 Halozyme Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
19 Feb

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), NeoGenomics (NEO) and Medtronic (MDT)

TIPRANKS
·
19 Feb

Halozyme price target raised to $72 from $70 at H.C. Wainwright

TIPRANKS
·
19 Feb

Halozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Highlights: Record Revenue and Strong ...

GuruFocus.com
·
19 Feb

JMP Securities Keeps Their Buy Rating on Halozyme (HALO)

TIPRANKS
·
19 Feb

Analysts Are Bullish on These Healthcare Stocks: Benitec Biopharma (BNTC), Halozyme (HALO)

TIPRANKS
·
19 Feb

Halozyme Therapeutics Achieves Record Revenue in 2024

TIPRANKS
·
19 Feb

Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks
·
19 Feb

Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates

Zacks
·
19 Feb

Halozyme Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
19 Feb

Halozyme Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
19 Feb

Halozyme Therapeutics Q4 Non-GAAP EPS, Revenue Increase

MT Newswires Live
·
19 Feb

Halozyme Therapeutics Q4 2024 Adj EPS $1.26 Beats $1.16 Estimate, Sales $298.00M Beat $288.24M Estimate

Benzinga
·
19 Feb

Halozyme Therapeutics Reiterates FY 2025 Guidance For EPS of $4.95-$5.35 on Revenue of $1.15-$1.225 Billion, vs FactSet Analyst Consensus of $4.90/Share on Revenue of $1.19 Billion

MT Newswires Live
·
19 Feb